Meta-Analysis
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5445-5453
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5445
Table 1 Characteristics of included studies
Ref.Inclusion criteriaRegionDiagnostic testNo. of patients (male %)Age, yr(mean ± SD)Intervention
Ang et al[36] (2015)Age > 21 yrSingaporeRUT, H, UBTC10: 153 (47.1)C10: 46.9 ± 14.810-d concomitant therapy
S10: 154 (59.7)S10: 47.5 ± 12.710-d sequential therapy
T10: 155 (58.1)T10: 49.8 ± 14.610-d triple therapy
Hsu et al[33] (2014)Age ≥ 20 yr, PU or gastritisTaiwanRUT, Cu, HC7: 102 (59.8)C7: 53.9 ± 12.37-d concomitant therapy
S10: 102 (50.9)S10: 55.0 ± 12.010-d sequential therapy
T7: 103 (60.2)T7: 56.1 ± 14.07-d triple therapy
Huang et al[22] (2012)Dyspepsia or epigastric discomfortTaiwanRUT, Cu, HC10: 84 (57.1)C10: 53.8 ± 15.210-d concomitant therapy
S10: 85 (56.7)S10: 51.3 ± 15.010-d sequential therapy
Tai et al[34] (2015)Age ≥ 20 yr, PU or gastritisTaiwanNot reportedC7: 92 (50.0)C7: 47.8 ± 11.67-d concomitant therapy
T7: 92 (49.0)T7: 52.8±12.87-d triple therapy
Wang et al[35] (2014)PU and gastritisChinaUBTC7: 81 (45.7)C7: 51 ± 137-d concomitant therapy
T7: 82 (42.7)T7: 51 ± 157-d triple therapy
T10: 83 (45.8)T10: 52 ± 1410-d triple therapy
Wu et al[20] (2010)Patients visited GI clinics with HP infectionTaiwanRUT, Cu, HC10: 115(52.2)C10: 51.8 ± 1110-d concomitant therapy
S10:117(52.1)S10: 51.7 ± 1210-d sequential therapy